Provided by Tiger Trade Technology Pte. Ltd.

CHINARES PHARMA

4.585
-0.065-1.40%
Volume:12.23M
Turnover:56.64M
Market Cap:28.81B
PE:6.11
High:4.710
Open:4.640
Low:4.585
Close:4.650
52wk High:6.336
52wk Low:4.211
Shares:6.28B
HK Float Shares:6.28B
Volume Ratio:1.25
T/O Rate:0.19%
Dividend:0.22
Dividend Rate:4.75%
EPS(LYR):0.750
ROE:8.32%
ROA:2.64%
PB:0.47
PE(LYR):6.11
PS:0.09

Loading ...

CHINARES PHARMA Subsidiary Completes RMB 1.4 Billion Corporate Bond Issuance

Stock News
·
Apr 28

华润医药2025业绩稳健增长,聚焦研发及业务布局优化

Bulletin Express
·
Apr 28

CHINARES PHARMA Releases 2025 ESG Report: Revenue Up 4.6%, Carbon Intensity Down 20% from 2020

Bulletin Express
·
Apr 28

China Resources Pharma publishes 2025 sustainability report

Reuters
·
Apr 28

China Resources Pharmaceutical publishes 2025 annual report

Reuters
·
Apr 28

China Resources Pharma Shares Slump Over 5% Following Mixed Q1 Results From Subsidiaries

Stock News
·
Apr 27

Dong-E-E-Jiao's Profit Jumps 7% in Q1, Revenue Up 5.5%

MT Newswires Live
·
Apr 27

Stock Track | CHINARES PHARMA Plummets 5.02% Intraday on Subsidiary's Profit and Revenue Decline

Stock Track
·
Apr 27

CR Double-Crane's Profit, Revenue Fall in Q1

MT Newswires Live
·
Apr 27

CR Boya Bio-pharmaceutical Q1 2026: Revenue Down 40.1% YoY, Net Profit Drops 78.4%

Bulletin Express
·
Apr 24

China Resources Pharmaceutical - Cr Boya Bio-Pharmaceutical Qtrly Unaudited Revenue RMB 321.1 Mln, Net Profit RMB 30.0 Mln

THOMSON REUTERS
·
Apr 24

China Resources Pharma subsidiary CR Boya Bio Q1 net profit falls to RMB 30 million

Reuters
·
Apr 24

CHINARES PHARMA's Unit Kpc Pharmaceuticals Swings to Q1 Loss

Stock News
·
Apr 24

China Resources Pharmaceutical Group Ltd - Kpc Q1 Net Loss at RMB 144.8 Mln

THOMSON REUTERS
·
Apr 24

China Resources Pharmaceutical Group Ltd - Kpc Q1 Revenue at RMB 836.2 Mln

THOMSON REUTERS
·
Apr 24

CR Sanjiu Q1 2026: Revenue Jumps 18.6% but Net Profit Slips 9.1%; Cash Outflow Weighs on China Resources Pharmaceutical Subsidiary

Bulletin Express
·
Apr 24

BRIEF-China Resources Pharmaceutical Says QTRLY Net Profit For CR Jiangzhong RMB312.0 MLN

Reuters
·
Apr 24

CHINARES PHARMA Subsidiary Tasly Pharmaceutical Delivers 5.35% Revenue and 9.78% Profit Growth in Q1 2026

Bulletin Express
·
Apr 24

CR Pharma’s Dong-E-E-Jiao Posts 7.1% Profit Growth in Q1 2026, Cash Reserves Surge

Bulletin Express
·
Apr 24

CR Double-Crane Q1 2026 Revenue Down 8.84%, Net Profit Declines 4.08%; Majority-Owned by CR Pharma

Bulletin Express
·
Apr 24